A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 700,200 shares of TVTX stock, worth $5.76 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
700,200
Previous 542,800 29.0%
Holding current value
$5.76 Million
Previous $4.88 Million 10.64%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$7.18 - $9.82 $1.13 Million - $1.55 Million
157,400 Added 29.0%
700,200 $5.4 Million
Q4 2023

Feb 14, 2024

SELL
$5.44 - $9.5 $185,504 - $323,950
-34,100 Reduced 5.91%
542,800 $4.88 Million
Q3 2023

Nov 14, 2023

SELL
$7.64 - $17.25 $824,356 - $1.86 Million
-107,900 Reduced 15.76%
576,900 $5.16 Million
Q2 2023

Aug 14, 2023

SELL
$15.3 - $22.61 $563,040 - $832,048
-36,800 Reduced 5.1%
684,800 $10.5 Million
Q1 2023

May 15, 2023

BUY
$17.82 - $22.89 $7.49 Million - $9.63 Million
420,500 Added 139.65%
721,600 $16.2 Million
Q4 2022

Feb 14, 2023

BUY
$18.47 - $26.14 $1.7 Million - $2.4 Million
92,000 Added 44.0%
301,100 $6.33 Million
Q3 2022

Nov 14, 2022

BUY
$22.91 - $28.63 $820,178 - $1.02 Million
35,800 Added 20.66%
209,100 $5.15 Million
Q2 2022

Aug 15, 2022

BUY
$20.94 - $30.01 $1.65 Million - $2.36 Million
78,600 Added 83.0%
173,300 $4.2 Million
Q1 2022

May 16, 2022

BUY
$23.61 - $30.6 $1.11 Million - $1.44 Million
47,000 Added 98.53%
94,700 $2.44 Million
Q4 2021

Feb 14, 2022

BUY
$24.34 - $31.17 $1.16 Million - $1.49 Million
47,700 New
47,700 $1.48 Million
Q2 2021

Aug 16, 2021

SELL
$14.11 - $26.4 $1.78 Million - $3.32 Million
-125,900 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$23.37 - $31.77 $740,829 - $1.01 Million
-31,700 Reduced 20.11%
125,900 $3.14 Million
Q4 2020

Feb 16, 2021

BUY
$19.17 - $27.87 $3.02 Million - $4.39 Million
157,600 New
157,600 $4.3 Million

Others Institutions Holding TVTX

About Travere Therapeutics, Inc.


  • Ticker TVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,173,600
  • Market Cap $528M
  • Description
  • Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...
More about TVTX
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.